Novel Sulfonylurea-Based NLRP3 Inflammasome Inhibitor for Efficient Treatment of Nonalcoholic Steatohepatitis, Endotoxic Shock, and Colitis
Journal of Medicinal Chemistry · 28.09.2023 · 66 (18) · 12966-12989
DOI: 10.1021/acs.jmedchem.3c00894 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 11.09.2023. Verfasst von Zhuoyue Li und 14 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Shock, Septic, Colitis. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: Taishan Scholar Foundation of Shandong Province, Fundamental Research Funds for the Central Universities, National Natural Science Foundation of China.
Abstract (Originalsprache)
The NLRP3 inflammasome is a critical component of innate immunity involved in the pathophysiology of various inflammatory diseases. In this study, we designed and synthesized a series of NLRP3 inflammasome inhibitors based on MCC950. Specifically, we optimized the furan moiety, which is considered to be potentially associated with drug-induced liver injury. The representative inhibitor N14, 4-(2-(dimethylamino)ethyl)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)benzenesulfonamide, not only maintains the NLRP3 inhibitory activity of MCC950 with IC50 of 25 nM but also demonstrates improved tolerability in human hepatic cells line and mouse primary hepatocytes. In addition, N14 exhibits superior pharmacokinetic properties, with an oral bioavailability of 85.2%. In vivo studies demonstrate that N14 is more effective than MCC950 in multiple NLRP3-related animal model diseases, including nonalcoholic steatohepatitis, lethal septic shock, and colitis. Our research has provided a lead compound that directly targets the NLRP3 inflammasome and can be developed as a novel therapeutic candidate for NLRP3-driven diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China.
- Center for Targeted Protein Degradation and Drug Discovery, Ocean University of China, Qingdao, Shandong 266003, China.
- College of Chemical Engineering, Qingdao University of Science and Technology, Qingdao 266042, China.
- Laboratory for Marine Drugs and Bioproducts, Qingdao National Laboratory for Marine Science and Technology, Qingdao 266003, China.
ORCID-Profile: Xiaoyang Li, Yuqi Jiang, Chong Qin
Förderung
- Taishan Scholar Foundation of Shandong Province
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China
Zitieren
APA
Li, Z., Chen, Y., Jiang, X., Lu, P., Wang, C., Li, Z., Yu, X., Yang, Z., Ma, S., Du, S., Tai, Z., Li, X., Zhang, S., Jiang, Y., & Qin, C. (2023). Novel Sulfonylurea-Based NLRP3 Inflammasome Inhibitor for Efficient Treatment of Nonalcoholic Steatohepatitis, Endotoxic Shock, and Colitis. Journal of Medicinal Chemistry, 66(18), 12966-12989. https://doi.org/10.1021/acs.jmedchem.3c00894
Vancouver
Li Z, Chen Y, Jiang X, Lu P, Wang C, Li Z, et al. Novel Sulfonylurea-Based NLRP3 Inflammasome Inhibitor for Efficient Treatment of Nonalcoholic Steatohepatitis, Endotoxic Shock, and Colitis. Journal of Medicinal Chemistry. 2023;66(18):12966-12989. doi:10.1021/acs.jmedchem.3c00894
BibTeX
@article{Li2023,
author = {Li, Zhuoyue and Chen, Yiming and Jiang, Xiaolin and Lu, Penghui and Wang, Chengli and Li, Zhimin and Yu, Xinyue and Yang, Zixuan and Ma, Shumin and Du, Shanshan and Tai, Zhengfu and Li, Xiaoyang and Zhang, Siqi and Jiang, Yuqi and Qin, Chong},
title = {Novel Sulfonylurea-Based NLRP3 Inflammasome Inhibitor for Efficient Treatment of Nonalcoholic Steatohepatitis, Endotoxic Shock, and Colitis},
journal = {Journal of Medicinal Chemistry},
year = {2023},
volume = {66},
number = {18},
pages = {12966--12989},
doi = {10.1021/acs.jmedchem.3c00894}
}
EUVIMED